The Regulatory Perspectives on Endoscopic Devices for Obesity.
Gastrointest Endosc Clin N Am
; 27(2): 327-341, 2017 Apr.
Article
en En
| MEDLINE
| ID: mdl-28292410
ABSTRACT
The recent increase in US Food and Drug Administration-approved weight-loss devices has diversified obesity treatment options. The regulatory pathways for endoscopically placed weight-loss devices and considerations for clinical trials are discussed, including the benefit-risk paradigm intended to aid in weight-loss-device trial development. Also discussed is the benefit-risk analysis of recently approved endoscopic devices. A strategic priority of the FDA Center for Devices and Radiological Health is to increase the use of patient input in decision making. Thus, we consider how endoscopic weight-loss devices with profiles similar to those that have been approved may be viewed in a patient preference study.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Endoscopía Gastrointestinal
/
Aprobación de Recursos
/
Cirugía Bariátrica
/
Obesidad
Tipo de estudio:
Prognostic_studies
Límite:
Humans
País/Región como asunto:
America do norte
Idioma:
En
Revista:
Gastrointest Endosc Clin N Am
Asunto de la revista:
DIAGNOSTICO POR IMAGEM
/
GASTROENTEROLOGIA
/
TERAPEUTICA
Año:
2017
Tipo del documento:
Article